SAT0180 A Multicenter, Open-Label, Long-Term Extension Study of Summacta and Brevacta to Evaluate Safety and Efficacy of Tocilizumab SC in Patients with Moderate to Severe RA

BackgroundTwo global Phase III studies evaluated the safety and efficacy of subcutaneous tocilizumab (TCZ-SC). SUMMACTA was a 97-week study that compared TCZ-SC 162 mg every week (qw) with intravenous TCZ (TCZ-IV) 8 mg/kg every 4 weeks. At week 24, patients (pts) were re-randomized to remain on the initially assigned formulation or switch to the other formulation. BREVACTA was a 96-week study that compared TCZ-SC 162 mg every 2 weeks (q2w) with placebo. From week 12 onward, pts could escape to TCZ-SC qw if they had